Background {#Sec1}
==========

Cardiovascular disease (CVD) is a growing cause of death and disability in sub-Saharan Africa (SSA). The Global Burden of Disease (GBD) 2010 study showed that, in 2000, ischemic heart disease and stroke accounted for 1.83 and 2.47 % respectively of total disability- adjusted life years (DALYs) lost in the region. A decade later there had been a 15 % increase in the percentage of total DALYs lost attributed to these conditions \[[@CR1]\]. This surge has been boosted by ongoing nutritional, demographic and epidemiological transitions. Costs ascribed to CVD are substantial; for example, in 2010, they amounted to about US\$11.6 billion in the World Health Organization's (WHO) African region E (AFRO E). These costs are expected to rise by 22 % by 2030 \[[@CR2]\]. Tanzania has not been spared from this tide, as evidence shows that the prevalence of CVD risk factors is increasing rapidly \[[@CR3]--[@CR8]\]. Consequently, large increases in avoidable CVD mortality and morbidity and hence serious pressures on the already constrained health systems are expected in the future unless preventive measures are implemented.

Many studies on the cost-effectiveness of preventive interventions into CVD have been conducted in high-income countries, with significant amounts of evidence in favour of primary prevention \[[@CR9]\]. Evidence from individual countries in SSA is extremely scarce \[[@CR10]--[@CR12]\]. Only a few studies focusing on interventions across WHO and World Bank developing regions are available \[[@CR13]--[@CR15]\], and their use of aggregated data from countries with great diversity in terms of demographic, epidemiological, socio-economic and policy contexts requires the results to be interpreted with caution when used to inform policy in individual countries.

Preventive cardiology in Tanzania not only receives low priority but it is also practised in a non-comprehensive way \[[@CR16]--[@CR18]\]. Tanzania's previous and current preventive guidelines \[[@CR19], [@CR20]\] focus unilaterally on single risk factors but this approach has been shown to be less effective than the absolute risk approach advocated in the WHO's CVD preventive guidelines and elsewhere \[[@CR10], [@CR16], [@CR21], [@CR22]\]. The absolute risk approach gives a numerical probability of a CVD event occurring in a given time period, e.g. one or ten years. It combines all modifiable major risk factors for CVD such as hypertension, cholesterol level and smoking. The absolute risk approach also includes unmodifiable factors like age and sex. Treatment decisions are then based on the total risk of a CVD event \[[@CR23]\].

There is a previous study that has explored the cost-effectiveness of medical preventive cardiology in Tanzania \[[@CR12]\]. Being the first, it forms an important step for further exploration on the subject. A new study is justifiable for the following reasons: firstly, the previous study did not explicitly model diabetes in its risk factor profile. Existing literature indicates that diabetes is one of the major risk factors for CVD \[[@CR24]\] and tends to occur together with other known cardiovascular risk factors \[[@CR25]\]. Secondly, primary cost data were not used in the estimation of intervention costs. Thirdly, the current work expands from a provider to a societal perspective by including costs to patients of receiving treatment. Fourthly, following the release of GBD 2010 \[[@CR26]\], new disability weights are available and the literature on drug effectiveness has since been updated. Finally, drugs such as simvastatin--which is listed on the national formulary and is currently available in Tanzania's Medical Stores Department (MSD)--have come off patent, and so are more likely to be affordable and therefore policy relevant for Tanzania. In light of the above reasons, the purpose of the present study is to perform a cost-effectiveness analysis of the most relevant medical interventions for primary prevention of CVD in Tanzania using an absolute risk approach.

Methods {#Sec2}
=======

Model structure {#Sec3}
---------------

Two Markov decision models for CVD risk without diabetes and CVD risk with diabetes--reflecting whether or not there is diabetes in addition to all other CVD risks--were constructed using TreeAge Pro 2014 software for four CVD risk cohorts. Further model details are specified in [Appendix 1](#Sec42){ref-type="sec"} to permit full replication of our results.

Absolute risk of CVD {#Sec4}
--------------------

We constructed index cohorts representing each of the four CVD risk levels (see [Appendix 1](#Sec42){ref-type="sec"}, Table 4) guided by the WHO's prediction charts for AFRO E. By varying age, gender, blood pressure, cholesterol level, smoking and diabetes status we obtained hypothetical cohorts representing low, medium, high and very high CVD risk levels, respectively \[[@CR22]\].

Description of interventions {#Sec5}
----------------------------

Table [1](#Tab1){ref-type="table"} below presents drug interventions included in the model.Table 1Drug interventions for primary prevention of CVDDrug classAcronymDrugDaily dosageAngiotensin converting enzyme inhibitorACEICaptopril12.5 mg twiceAngiotensin receptor blockerARBLosartan50 mg onceBeta blockerBBAtenolol50 mg onceBiguanideBigMetformin500 mg thriceCalcium channel blockerCCBNifedipine20 mg twiceSoluble aspirinASAAspirin75 mg onceStatinStaSimvastatin40 mg onceSulfonylureasSulfGlibenclamide5 mg onceThiazide diureticsDiuBendrofluazide2.5 mg or 5 mg once

These drugs are recommended by the WHO's CVD preventive guidelines \[[@CR22]\], except for angiotensin receptor blocker (ARB), which we included because its patent recently expired. For an overview of the drug combinations considered, see [Appendix 2](#Sec43){ref-type="sec"}.

Input parameters {#Sec6}
----------------

### Transition probabilities {#Sec7}

Annual risks for myocardial infarction (MI) and/or stroke were calculated from the Framingham Heart Study risk equations \[[@CR27], [@CR28]\] for the four different index cohorts. This was motivated by the absence of such data from the sub-Saharan region. Even though updated Framingham equations are available from the literature, these could not be applied in this work since the reported annual risks are combined for all CVD events \[[@CR29], [@CR30]\]. Age-specific background mortality rates were based on a Tanzanian life table \[[@CR31]\] and were adjusted for the mortality attributable to CVD \[[@CR32]\]. We used age and sex-specific case fatality rates from the WHO's CHOosing Interventions that are Cost-Effective (CHOICE) study \[[@CR33]\] ([Appendix 3](#Sec44){ref-type="sec"}, Table 5).

Since stroke was classified according to severity, information about the probabilities of "first ever stroke" and "subsequent stroke" was necessary. These were derived from context-specific literature and if data was unavailable we sought expert opinions or made assumptions ([Appendix 3](#Sec44){ref-type="sec"}, Table 6). We assumed that the probability of subsequent strokes after the second event was constant.

Intervention costs {#Sec8}
------------------

### Cost of CVD prevention and treatment {#Sec9}

The direct medical costs of providing medical primary prevention and cost to patients of receiving these services have been estimated elsewhere \[[@CR34]\]. The provider cost of CVD treatment was identified and measured according to standard protocols from Arusha urban hospital using an ingredients approach. Resource valuation followed the opportunity cost method. Unit costs were estimated using activity-based and step-down methodologies. Patient cost of receiving CVD treatment was assumed to be 57.5 % higher \[[@CR35]\] than the US\$123 estimated as the patient cost of receiving CVD preventive measures \[[@CR34]\]. The costing exercise follows a "narrow" societal perspective, whereby costs of health care, whether borne by the patient or the provider, are relevant. Since most economic evaluations are analyzed from the provider perspective only, a scenario analysis was conducted to explore the impact of this viewpoint on model recommendations. We assumed that primary preventive care can be performed within the existing facility setup and that upgrading of infrastructure is not required.

Intervention effects {#Sec10}
--------------------

The intervention effects--in terms of relative risk (RR)--of drug classes used were retrieved from systematic reviews and meta-analyses of relevant randomized controlled trials, except for oral hypoglycemics which were based on one randomized controlled trial (RCT), see [Appendix 3](#Sec44){ref-type="sec"}, Table 6 for references. [Appendix 4](#Sec45){ref-type="sec"} presents a summary of the comparators, RCT designs, statistical methods used and statements on primary prevention. The effects of interventions involving combinations of drugs were determined multiplicatively i.e. (RR~1~ × RR~2~ × RR~n~) \[[@CR36]\]. It was assumed that intervention effects did not vary across the different underlying risk groups and that it was constant across all age groups. We also assumed perfect adherence to treatment.

Health outcome {#Sec11}
--------------

We used DALYs, which combine years lived with disability (YLDs) and years of life lost (YLLs), as our measure of health outcomes. YLDs were based on GBD 2010 disability weights of 0.422 for acute myocardial infarction and 0.021, 0.076 and 0.539 for mild, moderate and severe stroke respectively \[[@CR26]\]. Tanzania's sex-specific life expectancy in 2012 and a disability weight of 1 to reflect the dead health state were used to calculate YLLs.

See Table [2](#Tab2){ref-type="table"} below for a summary of parameters and sources.Table 2Model parameters and data sourcesParameterSourcesAnnual risk of MI or stroke - Table [5](#Tab5){ref-type="table"}Framingham Heart StudyNon-MI or non-stroke mortality rate - Table [5](#Tab5){ref-type="table"}Tanzanian 2012 life table and GHDx datasetFatality rate from MI and stroke - Table [5](#Tab5){ref-type="table"}WHO, CHOICE studyCost of CVD prevention and treatment - Table [6](#Tab6){ref-type="table"}Authors' previous study and primary analysisIntervention costs and effects - Table [6](#Tab6){ref-type="table"}Tanzania MSD and meta-analysesDisability weights - Table [6](#Tab6){ref-type="table"}Global burden of disease 2010Other transition probabilities - Table [6](#Tab6){ref-type="table"}Cross-sectional studies and authors' extrapolation*MI* Myocardial infarction, *GHDx* Global Health Data Exchange, *WHO* World Health Organization, *CHOICE* CHOosing Interventions that are Cost-Effective, *MSD* Medical Stores Department

Cost-effectiveness analysis {#Sec12}
---------------------------

For the CVD risk both without and with diabetes, expected costs and outcomes were calculated for each of the possible interventions. Base-case results are presented as incremental costs and effects and incremental cost-effectiveness ratios (ICERs). Strategies having ICERs below US\$610, which is Tanzania's 2012 GDP per capita \[[@CR37]\], (the lowest willingness to pay (WTP) value recommended by the WHO \[[@CR38]\]) were considered "very cost-effective". In our base case, health costs and outcomes were non-differentially discounted at 3 % annually. A scenario analysis was conducted to test whether and how results vary with differential discounting. Age weighting was not incorporated into the analysis due to criticisms raised in the GBD 2010 study \[[@CR39]\].

Sensitivity analyses {#Sec13}
--------------------

The rationale behind performing a sensitivity analysis is that the uncertainty of the model parameters is mainly due to lack of data or ambiguity regarding how the data were collected, simplifications and assumptions made \[[@CR40], [@CR41]\]. A set of one-way sensitivity analyses was performed to evaluate the impact of single assumptions about costs and outcomes on model results. Upper and lower variable ranges were taken from the reported 95 % confidence interval or calculated from the standard error when stated. Otherwise we assumed a range of +/− 15 % around the base case value. In the multivariate probabilistic uncertainty analysis, using a Monte Carlo simulation, we ran the model with distributions for each parameter rather than point estimates to determine the probability of optimal intervention being cost-effective against a range of cost-effectiveness thresholds \[[@CR42], [@CR43]\].

Value of information analysis {#Sec14}
-----------------------------

High-quality evidence from multiple model input sources is not always available and decisions based on these model recommendations are subject to costly uncertainty. A value of information analysis allows for an estimation of the cost of existing uncertainty, which is determined by the function of the probability that a decision will be wrong for different levels of WTP for health and the size of the opportunity loss if the wrong decision is made \[[@CR44]\]. We first calculated expected value of perfect information (EVPI) as the difference between the expected net benefit with perfect information and current information, and then we estimated population EVPI assuming an annual effective hypothetical population of 1000 patients, discounted at a rate of 3 % for 10 years.

Results {#Sec15}
=======

Base-case results {#Sec16}
-----------------

Table [3](#Tab3){ref-type="table"} below presents the base-case results for the two distinct models "CVD risk" and "CVD risk with diabetes" for the four CVD risk levels. In the table, all dominated and extendedly dominated strategies have been excluded. The complete tables presenting cost, incremental cost, effectiveness and incremental effectiveness of all strategies are available from the authors by request.Table 3Base case results for CVD risk without and with diabetes for four risk levels. All dominated strategies have been excluded**CVD risk**StrategyCostICEffIEICERStrategyCostICEffIEICER**Low riskModerate risk**   No treatment4610.00No treatment15160.00   ACEI_Diu10055440.410.411327ACEI_Diu16831671.021.02164   ACEI_Diu_Sta12592540.490.083175ACEI_Diu_Sta18271441.280.26554**High riskVery high risk**   No treatment16950.00No treatment20280.00   ACEI_CCB_Diu22405451.561.56349ACEI_CCB_Diu_ASA324412162.442.44498   ACEI_CCB_Diu_Sta24041641.830.27607ACEI_CCB_Diu_Sta_ASA34331892.730.29652**CVD risk with diabetes**StrategyCostICEffIEICERStrategyCostICEffIEICER**Low riskModerate risk**   No treatment9640.00No treatment18050.00   Sulf_ACEI_CCB14815170.850.85608Sulf_ACEI_CCB19661611.401.40115   Big_Sulf_ACEI_CCB17782971.160.31958Big_Sulf_ACEI_CCB21221562.010.61256   Big_Sulf_ACEI_CCB_Sta20262481.260.102480Big_Sulf_ACEI_CCB_Sta23111892.210.20945**High riskVery high risk**   No treatment19090.00No treatment25140.00   Big_Sulf_ACEI_CCB25766672.162.16309Big_Sulf_ACEI_CCB_ASA369611823.383.38350   Big_Sulf_ACEI_CCB_Sta27681922.370.21914Big_Sulf_ACEI_CCB_Sta_ASA38931973.660.28704   Big_Sulf_ACEI_ARB_CCB_Sta379810302.470.1010300Big_Sulf_ACEI_ARB_CCB_Sta_ASA48839903.790.137615*IC* Incremental cost, *Eff* Effectiveness, *IE* Incremental effectiveness, *ICER* Incremental cost-effectiveness ratio

For both models, simpler treatment combinations appear most cost-effective for lower CVD risks, while higher risks led to more complex drug combinations being cost-effective. Generally, managing CVD risk is more cost-effective for patients with higher risk than for patients with lower risk, and more cost-effective for patients with diabetes than for patients without diabetes (Table [3](#Tab3){ref-type="table"}).

CVD risk {#Sec17}
--------

### Low risk {#Sec18}

The results suggest that providing a combination of ACEI and Diu averts 0.41 DALYs at a cost of US\$544 compared to no treatment, yielding the lowest ICER of US\$1327 per DALY averted. Adding Sta to this duotherapy averted a further 0.08 DALYs for US\$254.

### Moderate risk {#Sec19}

As for the low risk, ACEI and Diu yielded the lowest ICER of US\$164 per DALY averted. Providing this intervention averts 1.02 DALYs at a cost of US\$167 compared to giving no medical treatment.

### High risk {#Sec20}

The lowest ICER of US\$349 per DALY averted was shown to result from providing a triple therapy of ACEI, CCB and Diu to high-risk patients compared to no treatment, whereby a cost of US\$545 deterred 1.56 DALYs. Adding Sta to this combination requires an addition of US\$607 per DALY averted.

### Very high risk {#Sec21}

Out of the three non-dominated strategies, a combination of ACEI, CCB, Diu and ASA yielded the lowest ICER value of US\$498 per DALY averted compared to "no treatment", by averting 2.44 DALYs for US\$1216. Adding Sta to this combination required an additional US\$189 to prevent a further 0.29 DALYs (Table [3](#Tab3){ref-type="table"}).

CVD risk with diabetes {#Sec22}
----------------------

### Low risk {#Sec23}

Model conclusions for this risk level suggest that a combination of Sulf, ACEI and CCB averts 0.85 DALYs at a lifetime cost of US\$517, resulting in an ICER of US\$608 per DALY averted. Adding Big to this combination will prevent a further 0.31 DALYs at an additional cost of US\$297, with an ICER of US\$958 per DALY averted.

### Moderate risk {#Sec24}

As for the low risk with diabetes, the triple therapy of one oral hypoglycemic and two anti-hypertensives yielded the lowest ICER of US\$115 per DALY averted compared to not providing medical management. A more complex strategy of adding a second oral hypoglycemic required an additional US\$156 to deter a further 0.61 DALYs with an ICER of US\$256 per DALY averted.

### High risk {#Sec25}

Just over 2 DALYs are averted at a cost of US\$667 by giving two oral hypoglycemics (Big & Sulf) and two anti-hypertensives (ACEI & CCB), with an ICER of US\$309 per DALY averted. Additional DALYs are avoided at further cost and with more complex combinations. Adding Sta to this combination will further prevent 0.21 DALYs at a cost of US\$192 while further addition of ARB deterred only 0.10 DALYs at a cost of US\$1030. Corresponding ICERs are US\$914 and US\$10,300 per DALY averted respectively compared to the preceding interventions.

### Very high risk {#Sec26}

The lowest ICER was achieved by providing Big, Sulf, ACEI, CCB and ASA, whereby a cost of US\$1182 deterred 3.38 DALYs with an ICER of US\$350 per DALY averted.

Representing uncertainty {#Sec27}
------------------------

In this sub-section, only the results for low and very high CVD risk without and with diabetes are presented, due to space limitations. For the results for moderate and high risks see [Appendix 5](#Sec46){ref-type="sec"}.

Deterministic sensitivity analysis {#Sec28}
----------------------------------

Drug treatment effects are shown to be the most uncertain parameters for both low and very high CVD risk without and with diabetes. Variables representing less than 1 % of the total uncertainty were omitted since changing their assumptions had a negligible effect on the model. (Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}).Fig. 1ICER tornado diagrams for low and very high CVD risk. **a** Low CVD risk. **b** Very high CVD riskFig. 2ICER tornado diagrams for low and very high CVD risk with diabetes. **a** Low CVD risk with diabetes. **b** Very high CVD risk with diabetes

Probabilistic sensitivity analysis {#Sec29}
----------------------------------

Figures [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"} illustrate the optimal treatment paths, or cost-effectiveness acceptability frontiers (CEAFs), for low and very high CVD risk without and with diabetes for varying levels of plausible WTP to avert a DALY. For each level of WTP, the CEAFs illustrate only the optimal interventions with highest probability of being cost-effective, while all other alternatives are excluded.Fig. 3Cost-effectiveness acceptability frontier for low and very high CVD riskFig. 4Cost-effectiveness acceptability frontier for low and very high CVD risk with diabetes

CVD prevention is not likely to be cost-effective until WTP approaches US\$1327 and US\$498 per DALY averted in patients with low and very high CVD risk respectively. For low-risk patients, ACEI and Diu is optimal for all plausible levels of WTP higher than US\$1327 per DALY averted, while for very high-risk patients a combination of ACEI, CCB, Diu and ASA is most likely to be optimal within the WTP range of US\$498--US\$651 per DALY averted, after which a further addition of Sta becomes optimal.

For patients with diabetes, WTP values of about US\$608 and US\$350 for low and very high CVD risk, respectively are required for CVD prevention to be cost-effective compared to CVD risk without diabetes. For low-risk patients, a combination of Sulf, ACEI and CCB is optimal for WTP values between US\$608 and US\$958, followed by Big, Sulf, ACEI and CCB for a ceiling ratio exceeding US\$958. For very high-risk patients, a combination of Big, Sulf, ACEI, CCB and ASA is most likely to be optimal in the WTP range US\$350--US\$704 per DALY averted, after which the further addition of Sta becomes optimal.

The figures also illustrate that the above findings are surrounded by substantial uncertainty, except for patients with very high CVD risk and when WTP is very low (in which case no intervention is clearly optimal). For example, the ACEI and Diu combination in low-risk CVD patients without diabetes never exceeds a higher probability of being cost-effective than around 55 %, and consequently there is always at least a 45 % probability of the preferred strategy being sub-optimal. For low-risk patients with diabetes, the corresponding numbers are 75/25 % for the intervention Sulf, ACEI and CCB.

Expected value of perfect information (EVPI) analysis {#Sec30}
-----------------------------------------------------

Presented here are the EVPI analysis results for low and very high CVD risk without and with diabetes. The population EVPI--which represents the maximum amount of funds a decision-maker, should be willing to invest in research to eliminate all uncertainties--varied considerably with the different values of the WTP and risk levels ([Appendix 6](#Sec47){ref-type="sec"}).

From Fig. [5](#Fig5){ref-type="fig"} above, if Tanzanian's WTP is US\$610 then further research is potentially cost-effective for all risk levels except low CVD risk if the cost of proposed research is at most US\$160,000.Fig. 5Population EVPI curve for low and very high CVD risk without and with diabetes

Scenario analyses {#Sec31}
-----------------

### Societal vs provider perspective {#Sec32}

#### CVD risk: {#FPar1}

There were some changes in optimal therapies when the model was re-analyzed with patient costs excluded. For example, Diu as monotherapy became optimal for low and moderate risk levels, with ICERs of US\$723 and US\$092 per DALY averted respectively, and there was a re-emergence of BB in the non-dominated drug combinations for all risk levels ([Appendix 7](#Sec48){ref-type="sec"}).

#### CVD risk with diabetes: {#FPar2}

Model results remained largely the same for the CVD risk with diabetes model from the providers' perspective. We observed the strategies Sulf, ACEI and CCB being recommended for high-risk patients and Sulf, ACEI, CCB and ASA for very high-risk patients, whereas such combinations were dominated in our base case ([Appendix 7](#Sec48){ref-type="sec"}).

In both CVD risk without and with diabetes, model results from the societal perspective generally had lower ICERs compared to those from the provider viewpoint.

### Differential vs non-differential discounting {#Sec34}

Whether or not health outcomes are to be discounted (and at what rate) has raised a lot of debate in the field of economic evaluation \[[@CR41], [@CR45]--[@CR48]\]. Our base-case analysis was performed using non-differential discounting of 3 % for costs and health outcomes. We applied differential discounting in two forms, a lower discount rate (1.5 %) and no discount rate for health outcomes, while keeping the discount rate for costs constant at 3 %. Lower discount rates for health outcomes reduce the ICERs, making CVD prevention more attractive, but model recommendations in terms of rank ordering of the alternatives did not change. With a lower or no discount rate for health outcomes, more costly yet more effective strategies become optimal for lower levels of WTP ([Appendix 7](#Sec48){ref-type="sec"}).

### Different index cohort definition {#Sec35}

Our choice on index cohorts i.e. females for low risk and males for moderate to very high risk would imply that our main model results may not apply for males' low-risk patients and females' moderate to very high risks. We therefore constructed and re-run the model with a new set of index cohorts with the reverse gender and risk combinations ([Appendix 8](#Sec49){ref-type="sec"}, Tables 11 and 12). The model conclusions remain robust in terms of rank ordering of the different drug combinations, but higher willingness to pay values are required in order to recommend interventions to female compared to male patients (Table [3](#Tab3){ref-type="table"} and [Appendix 8](#Sec49){ref-type="sec"}, Table 13).

Discussion {#Sec36}
==========

This analysis suggests that multi-drug combinations achieve the best value for money for almost all risk levels both in the CVD risk and CVD risk with diabetes cohorts. If Tanzania is willing to pay up to US\$610--one Gross Domestic Product (GDP) per capita per DALY averted, below which interventions are considered to be very cost-effective by the WHO \[[@CR38]\]--our model recommends no medical treatment for low-risk without diabetes patients. For a moderate risk level without diabetes, a combination of ACEI and Diu has an ICER that falls below the tentative WTP threshold value. Adding CCB to this combination was the optimal choice for high-risk patients, while for very high-risk patients further adding ASA is suggested. For patients with diabetes, a combination of Sulf, ACEI and CCB is predicted to be optimal for low and moderate risk levels while adding Big to this combination consistently yielded more health for money for high and very high risk levels. For very high-risk patients, ASA was also part of the combination.

These conclusions are in line with the WHO's CVD preventive guidelines, which recommend no medical management for low CVD risks \[[@CR22]\]. We also observed similar results to those demonstrated in the cost-effectiveness analysis of primary prevention of CVD in Australia, where they recommended Diu, CCB, ACEI and Sta for all patients with a 5 % 5-year CVD risk. The same conclusion cannot be drawn for our moderate-risk patients since we assumed that triple anti-hypertensives were not clinically relevant for this risk level.

Our results are different from those of a similar study performed in Tanzania \[[@CR12]\], in which their recommended strategies, including combinations with BB, are dominated in our work. Differences in study perspectives, cost evidence, clinical evidence and choice of interventions analyzed meant that differences in optimal interventions were not unlikely. For example, interventions modelled in this work restricted ASA to very high-risk patients only and included ACEI in the drug combinations, which is not the case in the previous study. Comparing our model recommendations to the WHO-CHOICE study and a recent cost-effectiveness analysis to combat CVD in SSA and South East Asia results, we observed that drug combinations with Diu and BB were dominated and that our optimal strategies included combinations of ACEI with CCB or Diu. It is worth noticing that in these two studies only two anti-hypertensives, Diu and BB, were included, making comparability challenging \[[@CR13], [@CR49]\]. It suffices to say that we observed a re-emergence of BB in the recommended interventions in the scenario analysis from a provider perspective. This viewpoint was followed both in the former Tanzanian and WHO-CHOICE studies, making our results somewhat similar if the provider perspective was applied as base-case.

Our literature search revealed no studies analyzing options to prevent CVD in patients with diabetes. So we compared our results for this cohort with the WHO's CVD guidelines, which recommend metformin (biguanide) as the oral hypoglycemic drug of choice. We find that glibenclamide (sulfonylureas) is optimal for low and moderate-risk patients, while adding metformin to glibenclamide is likely to be optimal for higher risk levels.

Our decision rule is based on the WHO's proposed cost-effectiveness threshold of one times GDP per capita for Tanzania. This is because of the lack of a ceiling ratio set by Tanzania's decision-makers. However, the use of WHO's recommended cost-effectiveness benchmarks of one and three times GDP per capita \[[@CR38]\] has received some criticisms. The basis of this threshold is unclear; as such, it is not known whether it infers values based on previous decisions or is set to optimally determine or exhaust the healthcare budgets of some representative countries \[[@CR50]\]. Its use tends to make "almost" all healthcare interventions and programmes seem cost-effective and does not reflect the reality of resource constraints, hence challenging countries to introduce virtually any cost-effective interventions, which may end up with very low coverage and hence exacerbate healthcare inequalities \[[@CR51]\]. Tanzania should preferably determine its own ceiling ratio by tailoring its recommendations to its own budgetary constraints, epidemiological and demographic profile, existing health infrastructure and other health-system considerations. Several approaches have been proposed to define the value of willingness to pay ceilings \[[@CR50], [@CR52], [@CR53]\].

Most cost-effectiveness guidelines recommend a provider perspective in order to inform decisions about efficient use of healthcare resources \[[@CR54]\]. The societal perspective has also been proposed in some guidelines because it is more consistent with welfare economics. Whether it is possible to fully adopt a societal perspective in cost-effectiveness analysis has been discussed \[[@CR54]--[@CR56]\]. We do not claim to have adopted a broad societal perspective, but a rather "narrow" one since we only expanded the providers' perspective by including patient costs. The ICER results were more favourable from the societal than the provider perspective, which implies that ignoring patient costs could lead to sub-optimal resource allocation. It is equally true that including all relevant societal costs and benefits could significantly alter what we, in this work, consider to be very cost-effective.

Assuming the WTP value of US\$610 and a proposed cost of research of about US\$250,000, there will be value for further information for very high CVD risk without diabetes and low CVD risk with diabetes since their population EVPI exceeds the estimates of the proposed research. Current information regarding low CVD risk without diabetes is deem sufficient given its microscopic population EVPI value. Further exploration is required to determine what type of additional evidence would be most valuable and the most efficient research design \[[@CR44]\]. In practice, though, the value of research will be lower since some uncertainty will always remain.

Strengths and limitations {#Sec37}
-------------------------

We adopt a "narrow" societal perspective in this study by taking into account patient costs. This viewpoint captures societal benefits that are not captured from more restricted viewpoints \[[@CR56]\]. This work also analyzed interventions for all CVD risk levels, both without and with diabetes; although extensive, this permits comparisons within levels and between the two models for a better understanding of what does (or does not) work for each level of CVD risk.

These results should also be considered in light of model limitations. Firstly, the risk of myocardial infarction and stroke and drug treatment effects are based on data from trials carried out in developed countries, since good Tanzanian or regional data were unavailable. Secondly, effectiveness data for two drug classes (biguanide and glibenclamide) were extracted from one trial only, but again this was motivated by lack of data. Thirdly, we did not synthesize the evidence structure as we should have. Ideally, since most of our efficacy data were from trials with placebo as a comparator, indirect treatment comparisons (ITC) should have been performed and, in the very few instances where data was from other comparators, mixed treatment comparisons (MTC) should have been made. This weakness in inference concerning the relative efficacy of all treatments considered could possibly bias our results. However, these complex expansions of standard meta-analysis evidence are only as good as the trials included in them. Given the lack of a strong evidence base in our setting and since choices in healthcare resource allocation have to be made, we feel that our model results could, at this point, sufficiently inform these decisions \[[@CR57]\]. Fourthly, we did not account for non-adherence to treatment in our model for reasons of simplification and lack of data, and our model may therefore not reflect real adherence in long-term treatment. Non-adherence would likely reduce the efficacy of the pharmacological drugs modelled, which would pull result in the direction of less favourable ICER estimates. On the other side, nonadherence represents cost savings, which would pull in the opposite direction. The overall effect on the estimates is an empirical question, but our intuition is that the former effect would weight more heavily, and that low adherence potentially would make ICERs somewhat less attractive. Lastly, we should expect the effectiveness values of our interventions to be lower in practice than the ones used in this work since the efficacy data are extracted from a "controlled" trial setting.

Conclusion {#Sec38}
==========

Multiple drug combinations as a means of preventive cardiology yield ICERs lower than the proposed ceiling ratio of one GDP per capita for all risk levels except low CVD risk, which renders them very cost-effective. However, our model conclusions are surrounded by high uncertainty regarding both whether or not to treat and optimal treatment choice. The results of the value of information analysis suggest that it is potentially cost-effective to perform research to reduce uncertainties around model recommendations even at the lower WTP of US\$610. Decision-makers could therefore simultaneously adopt the model recommendations and consider further research, since the adoption decision is reversible. The fact that interventions are cost-effective given current information does not automatically mean that they should be recommended for implementation, since health systems usually have other recourse competing "very cost-effective" interventions that have not been fully implemented. There are also other objectives besides maximizing population health outcomes. Budget impact analysis and distributional concerns should be considered, for example, to assess governments' ability and to whom these benefits will accrue.

Ethical statement {#Sec39}
-----------------
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Availability of data and materials {#Sec40}
----------------------------------

The datasets supporting the conclusions of this article are included within the article and its [appendices](#Sec41){ref-type="sec"}.

Appendices {#Sec41}
==========

Appendix 1 {#Sec42}
----------

Cost-effectiveness model

The CVD prevention model is a probabilistic Markov model that provides information on health and healthcare costs over the lifetime of a hypothetical Tanzanian population (or population sub-groups). Two Markov decision models for CVD risk without diabetes and CVD risk with diabetes were constructed using TreeAge Pro 2014 software (Figure 6) for four CVD risk cohorts. Modelling them separately was necessary since CVD have different risk and treatment profiles depending on whether or not the patient is diabetic.Fig. 6Model structure - CVD primary prevention

Six mutually exclusive health states were considered: "no history of CVD" (i.e. no previous myocardial infarction or stroke), "history of myocardial infarction", and "history of stroke". Finally, "death" was modelled as an absorbing state. Stroke was modelled in three different health states based on severity: "mild", "moderate" or "severe", in order to be consistent with disability weights reported in the GBD 2010 \[[@CR26]\].

A cohort of healthy individuals with "no history of CVD" first enters the model at the age of 40 years. The cohort then transits between the different health states according to age-specific risks for each type of clinical event and depending on the risk reduction from the alternative preventive drugs. Each type of health state incurs costs and changes in health outcomes which are re-calculated after every annual cycle. A 60-year time horizon was considered to reflect the chronic nature of CVD.

In each model, "no treatment" was the baseline strategy and was compared with different medical interventions (singly or in combination) for primary prevention of CVD. The inclusion of "no treatment" as a comparator was important to allow for low-risk groups for whom treatment is not likely to be cost-effective. In order to explore the effects of the interventions in different populations, four distinct sub-models were created to represent four CVD risk levels: low risk, moderate risk, high risk and very high risk with a 10-year risk of CVD event of \< 10 %, 10-19 %, 20-30 % and \>30 % respectively.
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Fig. 7Interventions analysed for each CVD risk level

Figure 7 presents the strategies analyzed in the CVD model diagrammatically. For low and moderate CVD risk, the strategies modelled are represented by "Package LM", which consists of individual anti-hypertensives ACEI, ARB, BB, CCB and Diu in mono and duotherapy as shown by the inner circle in the diagram under the label "Low and moderate risk". Package LM is then combined with statin, e.g. ACEI + statin, ACEI + ARB + statin etc. represented by the "statin circle" embedded in the inner circle. Third, statin alone is also analyzed for this risk level and lastly "no treatment" option is also included, making a total of 32 interventions modelled.

Interventions modelled for high risk consist of: (i) All the interventions under Package LM, i.e. the 15 anti-hypertensives in mono and duo therapy, (ii) "Package H" which is anti-hypertensives in triple therapy - a total of 10 options, (iii) Package LM and Package H combined with statin, e.g. ACEI + statin, ACEI + ARB + statin, ACEI + ARB + BB + statin. (iv) No treatment option. Fifty-one (51) interventions were analyzed for this risk level.

Lastly, strategies considered for very high-risk patients are interventions analyzed under Package LM and Package H but now combined with soluble aspirin, e.g. ACEI + ASA, ACEI + ARB + ASA, ACEI + ARB + BB + ASA, represented by the inner circle with "ASA circle" embedded within it in the diagram under "Very high risk". These interventions are marked "Package VH". All these combinations are then combined with statin, e.g. ACEI + ASA + statin, ACEI + ARB + ASA + statin, ACEI + ARB + BB + ASA + statin. With the no treatment option, the strategies made up a total of 51 interventions modelled.Fig. 8Interventions analysed for each CVD with diabetes risk level

The same approach can be used to interpret these diagrams, indicating the interventions analyzed for the four levels of CVD risk with diabetes. A total of 43 interventions were modelled for low and moderate CVD with diabetes risk levels while the number was 49 options for high and very high CVD with diabetes risk levels.

As depicted in Figure 8, drug combinations considered in the analysis consisted of up to two antihypertensives together with other drug classes for low and moderate risks. For these levels we assumed that combinations of three anti-hypertensives are clinically irrelevant. All other possible combinations without and with soluble aspirin were modelled for high and very high risks respectively. Soluble aspirin was included only for very high-risk patients, where it has been shown to be more beneficial than harmful \[[@CR22]\].
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Table 5Annual risk of acute myocardial infarction and stroke, background mortality and case fatality ratesNo previous history of acute myocardial infarction (AMI) or strokeCVD riskAcute myocardial infarctionStroke AgeLowModerateHighVery highLowModerateHighVery high 40-490.00200.01300.01600.02300.00200.00500.00600.0100 50-590.00400.01900.02300.03100.00200.00500.00700.0110 60-690.00600.02900.03100.04000.00400.00700.01000.0150 70-790.00600.03600.03800.04400.00600.01100.01500.0220 80-890.00700.03900.04300.05200.01100.01700.02200.0330 90-990.00800.04400.04800.05700.01900.01900.03600.0460CVD risk with diabetes 40-490.00500.01400.01400.02900.00300.00600.00800.0130 50-590.00800.02100.02100.03800.00400.00700.01000.0150 60-690.01200.02700.02900.04400.00600.01000.01300.0200 70-790.01300.02900.03100.04600.01100.01500.02000.0290 80-890.01400.03500.03700.05700.01900.02200.02900.0420 90-990.01600.03900.04300.06200.03200.02900.03500.0630With previous history of AMI or strokeCVD riskAcute myocardial infarctionStroke AgeLowModerateHighVery highLowModerateHighVery high 40-490.00210.01430.01840.02760.00230.00590.00720.0133 50-590.00420.02090.02650.03720.00230.00590.00840.0146 60-690.00630.03190.03570.04800.00450.00820.01200.0200 70-790.00630.03960.04370.05280.00680.01290.01800.0293 80-890.00740.04290.04950.06240.01240.01990.02640.0439 90-990.00840.04840.05520.06840.02150.02220.04320.0612CVD risk with diabetes 40-490.00530.01540.01610.03480.00340.00700.00960.0173 50-590.00840.02310.02420.04560.00450.00820.01200.0200 60-690.01260.02970.03340.05280.00680.01170.01560.0266 70-790.01370.03190.03570.05520.01240.01760.02400.0386 80-890.01470.03850.04260.06840.02150.02570.03480.0559 90-990.01680.04290.04950.07440.03620.03390.04200.0838Case Fatality rateAcute myocardial infarctionStrokeBackground mortality AgeMalesFemalesMalesFemalesAge 40-490.30400.40700.34700.352040-490.0112 50-590.31100.41200.24800.198050-590.0120 60-690.33600.43000.28300.252060-690.0225 70-790.36700.45100.42000.412070-790.0467 80-890.40900.48400.64200.665080-890.1006 90-990.45100.51700.79200.815090-990.1458Table 6Intervention effects, costs, disability weights and other transition probabilitiesParameterModel input§ *(95 % CI)*Sourcea. Intervention effects and costs Angiotensin converting enzyme inhibitor  RR^1^MI^2^*0.81(0.70 - 0.94)*\[[@CR58]\]Stroke*0.65(0.52 - 0.82)*  Cost^3^14.10\[[@CR59]\] Angiotensin receptor blocker  RRMI0.94 *(0.85 - 1.03)*\[[@CR60]\]Stroke*0.91(0.85 - 0.98)*  Cost64.83\[[@CR59]\] Beta-blocker  RRMI0.90 *(0.78 - 1.03)*\[[@CR58]\]Stroke0.83 *(0.72 - 0.97)*  Cost6.82\[[@CR59]\] Biguanide  RRMI0.67 *(0.51 - 0.89)*\[[@CR61]\]Stroke0.80 *(0.50 - 1.27)*  Cost21.15\[[@CR59]\] Calcium channel blocker  RRMI0.85 *(0.78 - 0.92)*\[[@CR62]\]Stroke0.66 *(0.58 - 0.75)*  Cost13.19\[[@CR59]\] Soluble Aspirin  RRMI0.77 *(0.69 - 0.86)*\[[@CR63]\]Stroke0.95 *(0.85 - 1.06)*  Cost14.79\[[@CR59]\] Statin  RRMI0.86 *(0.82 - 0.90)*\[[@CR64]\]Stroke0.90 *(0.85 - 0.95)*  Cost15.92\[[@CR59]\] Sulfonylureas  RRMI0.85 *(0.74 - 0.97)*\[[@CR61]\]Stroke0.91 *(0.73 - 1.13)*  Cost6.37\[[@CR59]\] Thiazide diuretics  RRMI0.84 *(0.75 - 0.95)*\[[@CR58]\]Stroke0.63 *(0.57 - 0.71)*  Cost1.18\[[@CR59]\]b. Costs Cost of CVD^4^ prevention  Patient cost per OPD^5^ visit15.1\[[@CR34]\]¶  Provider cost per OPD visit7.15  Provider cost per lab test4.07 Cost of CVD treatment  Patient cost per CVD treatment194\[[@CR35]\]MIMild strokeMod.^6^ strokeSev.^7^ stroke CVD risk - first year310271512570Estimation CVD risk - subsequent years2606776313 CVD risk with diabetes - first year358319560594 CVD risk with diabetes - subsequent years308115124361c. Disability weights^8^ Acute MI0.42 *(0.28 - 0.57)*\[[@CR26]\] Mild stroke0.02 *(0.01 - 0.04)* Moderate stroke0.08 *(0.05 - 0.11)* Severe stroke0.54 *(0.36 - 0.71)*d. Other probabilities In the event of a first ever stroke, what is the probability of a:  mild stroke for a CVD risk0.19\[[@CR65], [@CR66]\]  moderate for a CVD risk0.44Extrapolation  severe for a CVD risk0.27and  mild stroke for a CVD risk with diabetes0.15assumptions  moderate for a CVD risk with diabetes0.35  severe for a CVD risk with diabetes0.50 In the event of a subsequent stroke, what is the probability of:  ...mild stroke0.15  ...moderate stroke0.25  ...severe stroke0.60^1^RR - Relative risk with beta distribution fitted; ^2^MI - Myocardial in arction; ^3^Cost - All costs are in 2012 US\$ and were fitted with a gamma distribution; ^4^CVD - Cardiovascular disease; ^5^OPD - Out-patient department; ^6^Mod. - Moderate; ^7^Sev. - Severe; ^8^Beta distribution was fitted disability weights and other probabilities; §All model parameters were varied at ± 15 % unless stated; ¶ provider cost per OPD visit is the average cost per visit for the four facilities costed, provider cost per lab test available from Table 5, Patient cost per OPD visit was derived from annual patient cost divided by average number of clinic visits \[[@CR34]\].
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Table 7Summary of meta-analyses and individual trials from which intervention effects were extractedDrug classTrialsDrug namesComparatorTypeBlindedStatistical methodNotesACEI3Ramipril, Deserpidine,PlaceboMADouble\*RR, M-H, fixed, Chi^2^72 % PPPerindopril, CaptoprilARB17Cardisartan, Valsartan,PlaceboMANR\~RR, random, fixed, I^2^NRIrbesartan, Telmisartan, LorsartanASA6Soluble aspirinPlacebo^1^MABlindedƪRate ratio, NS, *X* ^2^PP trials onlyBB5Propanolol, AtenololPlaceboMADouble§RR, M-H, fixed, Chi^2^72 % PPBig1MetforminConventional therapyRCTsNoNANACCB22▪NRPlaceboMADouble†RR, M-H, fixed, Chi^2^NRDiu19Indapamide, CHTD, Chlorothiazide,PlaceboMADouble¶RR, M-H, fixed, Chi^2^72 % PPHCTZ, Bendrofluazide, T richloromethiazideSta10Pravastatin, Lovastatin,Placebo,UC^2^ or diet^3^MADouble‡OR, random, fixed, I^2^80 % PP or separate note on PPArtorvastatin, Simvastatin, RosuvastatinSulf1Sulfonylureas-insulinConventional therapyRCTsNoNANAACEI - Angiotensin Converting Enzyme Inhibitor, ARB - Angiotensin Receptor Blocker, Asp - Soluble Aspirin, BB - Beta Blocker, Big - Biguanide, CCB - Calcium Channel Blocker, Diu - Diuretic, Sta - Statins, Sulf - Sulfonylureas, CHTD - Chlorothalidone, HCTZ - Hydrochlorothiazide, UC - usual care, MA - Meta analyses, RCTs - Randomized Controlled Trials, NR - Not reported, RR - Relative risk, M-H - Mantel Haenszel, OR - Odds ratio, PP - Primary prevention, SP - Secondary prevention, NA - Not applicable, 22▪ - These are trials which reported MI events; 9 reported stroke events, Double\* - two trials were open label, NR \~ − Even though blinding was not reported it was considered in trial quality, Placebo1 - Two trials compared aspirin with no comparator and open-label vitamin E, Blindedƪ - Two trials were open trials, Double§ - One trial was single blinded and one open trial, Double† - One trial was not blinded, Double¶ - Four trials were single blinded and three trials were open, Double‡ - Blinding status was not reported for one trial. For those drug classes which were not compared with placebo, we assume that comparability between different drug classes remains valid since a non- pharmacological agent was used. Ideally a mixed treatment comparison analysis should have been performed with all the drug classes whose comparator was not a placebo
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Fig. 9ICER tornado diagrams for moderate and high CVD risk. **a** Moderate CVD risk. **b** High CVD riskFig. 10ICER tornado diagrams for moderate and high CVD risk with diabetes. **a** Moderate CVD risk with diabetes. **b** High CVD risk with diabetesFig. 11Cost effectiveness acceptability frontier for moderate and high CVD riskFig. 12Cost effectiveness acceptability frontier for moderate and high CVD risk with diabetes
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Table 8Expected Value of Perfect Information (EVPI) and population EVPI^1^ according to CVD risk levelsLow riskModerate riskHigh riskVery high riskWTP value (\$)EVPIpop EVPIEVPIpop EVPIEVPIpop EVPIEVPIpop EVPI CVD risk  3050.00.044382196433794560.21413  6100.00.0585090696254586351450067  915017683574984104741259937320778  122025223152675906304842405136319205  152538331920807006925245730439342096  183035305884938200135649626142370022 CVD risk with diabetes  3050.22027554825499381630538330960  61038338058141233271614235118160405  9156859477621182611262262980871701  122037324309098052507630770111007  152519166059032251102133930.22188  1830131156020167110.329370.1893^1^ Population EVPI for 1000 patients, 10 years, 3 % discount rate; pop - population; WTP - Willingness to pay
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Table 9Provider perspective results for four CVD risk levels without and with diabetes. All dominated strategies have been excluded**CVD risk**StrategyCostICEffIEICERStrategyCostICEffIEICER  **Low riskModerate risk**  No treatment2500.00No treatment8550.00  Diu4091590.220.22723Diu9030480.520.52092  BB Diu5080990.320.10990BB Diu9450420.770.25168  ACEI Diu6171090.410.091211ACEI Diu10000551.020.25220  ACEI Diu Sta8842670.490.083338ACEI Diu Sta11881881.280.26723  **High riskVery high risk**  No treatment9550.00No treatment11610.00  ACEI BB Diu12783231.401.40231ACEI BB Diu ASA18316702.272.27295  ACEI CCB Diu13470691.560.16431ACEI CCB Diu ASA19050742.470.20370  ACEI CCB Diu Sta15482011.830.27744ACEI CCB Diu Sta ASA21182132.760.29735**CVD risk with diabetes**StrategyCostICEffIEICERStrategyCostICEffIEICER  **Low riskModerate risk**  No treatment5480.00No treatment10990.00  Sulf ACEI CCB10274790.850.85564Sulf ACEI CCB13042051.401.40146  Big Sulf ACEI CCB13713441.160.311110Big Sulf ACEI CCB15612572.010.61421  Big Sulf ACEI CCB Sta16332621.260.102620Big Sulf ACEI CCB Sta17832222.210.201110  **High riskVery high risk**  No treatment11600.00No treatment15160.00  Sulf ACEI CCB14793191.521.52210Sulf ACEI CCB ASA20675512.542.54217  Big Sulf ACEI CCB17572782.160.64434Big Sulf ACEI CCB23652983.360.82363  Big Sulf ACEI CCB Sta19782212.370.211052Big Sulf ACEI CCB Sta ASA25842193.640.28782  Big Sulf ACEI ARB CCB Sta302210442.470.1010440Big Sulf ACEI ARB CCB Sta ASA358510013.770.137700IC - Incremental cost; Eff - Effectiveness; IE - Incremental effectiveness; ICER - Incremental cost-effectiveness ratioTable 10Differential discounting results for CVD risk without and with diabetes for four risk levels. All dominated strategies have been excludedBase caseLower DRNo DRBase caseLower DRNo DRStrategyoDR - 3 %oDR - 1.5 %oDR - 0 %StrategyoDR - 3 %oDR - 1.5 %oDR - 0 %**CVD risk**  **Low risk**ICER**Moderate risk**ICER  No treatmentNo treatment  ACEI_Diu1327907585ACEI_Diu164118082  ACEI_Diu_Sta317521211497ACEI_Diu_Sta554379262  **High riskVery high risk**  No treatmentNo treatment  ACEI_CCB_Diu349252176ACEI_CCB_Diu_ASA498364258  ACEI_CCB_Diu_Sta607432293ACEI_CCB_Diu_Sta_ASA652461315**CVD risk with diabetes**  **Low riskModerate risk**  No treatmentNo treatment  Sulf_ACEI_CCB608465311Sulf_ACEI_CCB115083058  Big_Sulf_ACEI_CCB958645430Big_Sulf_ACEI_CCB256179123  Big_Sulf_ACEI_CCB_Sta248017691126Big_Sulf_ACEI_CCB_Sta945675450  **High riskVery high risk**  No treatmentNo treatment  Big_Sulf_ACEI_CCB309222154Big_Sulf_ACEI_CCB_ASA350258184  Big_Sulf_ACEI_CCB_Sta914640436Big Sulf ACEI CCB Sta ASA704505346  Big Sulf ACEI ARB CCB Sta1030073574905Big Sulf ACEI ARB CCB Sta ASA761549503536DR - Discount rate; ICER - Incremental cost-effectiveness ratio
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Table 11Index cohort's characteristics according to CVD risk levels\*Index cohortLow riskModerate riskHigh riskVery high riskWithout diabetes Total cholesterol4 mmol\>8 mmol^1^\>8 mmol\>8 mmol Systolic blood pressure120-139 mmHg140-159 mmHg^2^160-179 mmHg\>180 mmHg SmokingNoNoNoYes SexMaleFemaleFemaleFemaleWith diabetes Total cholesterol4 mmol6 mmol7 mmol^4^\>8 mmol Systolic blood pressure120-139 mmHg140-159 mmHg^3^160-179 mmHg160-179 mmHg SmokingNoNoNoYes SexMaleFemaleFemaleFemale\*These are the index characteristics of the genders not represented in tie main results. Age groups were: 40--49, 50--59, 60--69, 70--79, 80--89 and 90--99 (Table [12](#Tab12){ref-type="table"}); ^1^7 mmol used for age group 40--49; ^2^160-179 mmHg applied to age group 40--49; ^3^160-179 mmHg used for age groups 40--59; ^4^6 mmol used for age groups \> 60 yearsTable 12Annual risk of acute myocardial infarction and stroke for low CVD risk males and moderate to very high CVD risk femalesNo previous history of acute myocardial infarction (AMI) or strokeCVD riskAcute myocardial infarctionStroke AgeLowModerateHighVery highLowModerateHighVery high 40-490.00400.00800.01000.01800.00400.00300.00300.0080 50-590.00600.01400.01600.02500.00400.00300.00400.0090 60-690.01000.01800.02100.03100.00500.00500.00600.0160 70-790.01400.01900.02300.03300.00800.00900.01100.0270 80-890.01900.02100.02500.03600.01300.01600.01900.0430 90-990.02300.02300.02700.03800.01500.02700.03200.0640CVD risk with diabetes 40-490.00600.01300.01600.02700.00500.00500.00500.0090 50-590.00900.01900.02300.03600.00500.00600.00600.0110 60-690.01400.02100.02500.04200.00700.00900.01100.0190 70-790.01900.02300.02700.04400.01100.01600.01900.0320 80-890.02400.02500.02900.05100.01700.02700.03200.0500 90-990.02900.02700.03100.05600.01900.04300.05000.0710With previous history of AMI or strokeCVD riskAcute myocardial infarctionStroke AgeLowModerateHighVery highLowModerateHighVery high 40-490.00420.00880.01150.02160.00450.00350.00360.0106 50-590.00630.01540.01840.03000.00450.00350.00480.0120 60-690.01050.01980.02420.03720.00570.00590.00720.0213 70-790.01470.02090.02650.03960.00900.01050.01320.0359 80-890.02000.02310.02880.04320.01470.01870.02280.0572 90-990.02420.02530.03110.04560.01700.03160.03840.0851CVD risk with diabetes 40-490.00630.01430.01840.03240.00570.00590.00600.0120 50-590.00950.02090.02650.04320.00570.00700.00720.0146 60-690.01470.02310.02880.05040.00790.01050.01320.0253 70-790.02000.02530.03110.05280.01240.01870.02280.0426 80-890.02520.02750.03340.06120.01920.03160.03840.0665 90-990.03050.02970.03570.06720.02150.05030.06000.0944Table 13Cost-effectiveness results for low CVD risk males and moderate to very high CVD risk females without and with diabetes. All dominated strategies have been excluded**CVD risk**StrategyCostICEffIEICERStrategyCostICEffIEICER  **Low riskModerate risk**  No treatment7990.00No treatment9910.00  ACEI Diu12024030.610.61661ACEI Diu13303390.820.82413  ACEI Diu Sta14242220.740.131708ACEI Diu Sta15251951.020.20975  **High riskVery high risk**  No treatment11120.00No treatment15910.00  ACEI CCB Diu19418291.221.22680ACEI CCB Diu ASA305914682.302.30638  ACEI CCB Diu Sta21522111.430.211005ACEI CCB Diu Sta ASA32772182.560.26838**CVD risk with diabetes**StrategyCostICEffIEICERStrategyCostICEffIEICER  **Low riskModerate risk**  No treatment11750.00No treatment14670.00  Sulf ACEI CCB16194440.950.95467Sulf ACEI CCB17562891.361.36213  Big Sulf ACEI CCB18782591.300.35740Big Sulf ACEI CCB19712151.940.58371  Big Sulf ACEI CCB Sta21102321.420.121933Big Sulf ACEI CCB Sta21822112.130.191111  **High riskVery high risk**  No treatment16020.00No treatment20600.00  Big Sulf ACEI CCB24468442.172.17389Big Sulf ACEI CCB ASA353914793.373.37439  Big Sulf ACEI CCB Sta26542082.380.21991Big Sulf ACEI CCB Sta ASA37572183.640.27807  Big Sulf ACEI ARB CCB Sta370010462.480.1010460Big Sulf ACEI ARB CCB Sta ASA477010133.770.137792IC - Incremental cost; Eff - Effectiveness; IE - Incremental effectiveness; ICER - Incremental cost-effectiveness ratio

ACEI

:   angiotensin converting enzyme inhibitor

AFRO E

:   African region E

ARB

:   angiotensin receptor blocker

ASA

:   soluble aspirin

BB

:   beta blocker

Big

:   biguanide

CCB

:   calcium channel blockers

CEAF

:   cost-effectiveness acceptability frontier

CHOICE

:   CHOosing interventions that are cost-effective

CVD

:   cardiovascular disease

DALY

:   disability- adjusted life years

Diu

:   diuretics

Eff

:   effectiveness

EVPI

:   expected value of perfect information

GBD

:   global burden of disease

GDP

:   gross domestic product

GHDx

:   Global Health Data Exchange

IC

:   incremental cost

ICER

:   incremental cost-effectiveness ratio

IE

:   incremental effectiveness

ITC

:   indirect treatment comparison

MI

:   myocardial infarction

MSD

:   Medical Stores Department

MTC

:   mixed treatment comparison

RCT

:   randomized control trial

RR

:   relative risk

SSA

:   sub-Saharan Africa

Sta

:   statin

Sulf

:   sulfonylureas

US\$

:   United States of America dollar

WHO

:   World Health Organization

WTP

:   willingness to pay

YLDs

:   years lived with disability

YLLs

:   years of life lost
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